ARGENX SE (1AE.DE) Stock Fundamental Analysis
Europe - FRA:1AE - NL0010832176 - Common Stock
745.6 EUR
+15.6 (+2.14%)
Overall 1AE gets a fundamental rating of 6 out of 10. We evaluated 1AE against 74 industry peers in the Biotechnology industry. 1AE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 1AE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
1AE had positive earnings in the past year.
In the past year 1AE had a positive cash flow from operations.
1AE had negative earnings in 4 of the past 5 years.
1AE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of 1AE (17.84%) is better than 91.89% of its industry peers.
Looking at the Return On Equity, with a value of 21.00%, 1AE belongs to the top of the industry, outperforming 90.54% of the companies in the same industry.
The Return On Invested Capital of 1AE (5.36%) is better than 82.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.36% |
ROA(3y)-5.23%
ROA(5y)N/A
ROE(3y)-5.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1AE's Profit Margin of 41.97% is amongst the best of the industry. 1AE outperforms 93.24% of its industry peers.
1AE has a better Operating Margin (15.30%) than 85.14% of its industry peers.
The Gross Margin of 1AE (89.40%) is better than 85.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1AE is destroying value.
The number of shares outstanding for 1AE has been increased compared to 1 year ago.
Compared to 1 year ago, 1AE has a worse debt to assets ratio.
2.2 Solvency
1AE has an Altman-Z score of 30.94. This indicates that 1AE is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 1AE (30.94) is better than 98.65% of its industry peers.
The Debt to FCF ratio of 1AE is 0.14, which is an excellent value as it means it would take 1AE, only 0.14 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.14, 1AE belongs to the best of the industry, outperforming 93.24% of the companies in the same industry.
1AE has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
1AE has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. 1AE outperforms 82.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 30.94 |
ROIC/WACC0.71
WACC7.52%
2.3 Liquidity
A Current Ratio of 5.60 indicates that 1AE has no problem at all paying its short term obligations.
1AE has a better Current ratio (5.60) than 81.08% of its industry peers.
1AE has a Quick Ratio of 5.27. This indicates that 1AE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.27, 1AE belongs to the top of the industry, outperforming 82.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1512.50% over the past year.
Looking at the last year, 1AE shows a very strong growth in Revenue. The Revenue has grown by 64.65%.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%96.6%
3.2 Future
The Earnings Per Share is expected to grow by 106.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 33.99% on average over the next years. This is a very strong growth
EPS Next Y867.29%
EPS Next 2Y297.24%
EPS Next 3Y171.03%
EPS Next 5Y106.11%
Revenue Next Year89.57%
Revenue Next 2Y60.07%
Revenue Next 3Y45.87%
Revenue Next 5Y33.99%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
1AE is valuated quite expensively with a Price/Earnings ratio of 69.42.
Based on the Price/Earnings ratio, 1AE is valued a bit cheaper than the industry average as 78.38% of the companies are valued more expensively.
1AE is valuated expensively when we compare the Price/Earnings ratio to 26.35, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 31.60, the valuation of 1AE can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1AE indicates a rather cheap valuation: 1AE is cheaper than 82.43% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 33.72, 1AE is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 69.42 | ||
| Fwd PE | 31.6 |
4.2 Price Multiples
1AE's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1AE is cheaper than 72.97% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1AE indicates a rather cheap valuation: 1AE is cheaper than 81.08% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 172.06 | ||
| EV/EBITDA | 96.95 |
4.3 Compensation for Growth
1AE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1AE's earnings are expected to grow with 171.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y297.24%
EPS Next 3Y171.03%
5. Dividend
5.1 Amount
No dividends for 1AE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:1AE (11/10/2025, 7:00:00 PM)
745.6
+15.6 (+2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.51%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap45.91B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts84.8
Price Target738.52 (-0.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)3.52%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.34%
PT rev (3m)N/A
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.84%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.56%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.3%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 69.42 | ||
| Fwd PE | 31.6 | ||
| P/S | 17.41 | ||
| P/FCF | 172.06 | ||
| P/OCF | 131.56 | ||
| P/B | 8.71 | ||
| P/tB | 9.04 | ||
| EV/EBITDA | 96.95 |
EPS(TTM)10.74
EY1.44%
EPS(NY)23.59
Fwd EY3.16%
FCF(TTM)4.33
FCFY0.58%
OCF(TTM)5.67
OCFY0.76%
SpS42.83
BVpS85.56
TBVpS82.49
PEG (NY)0.08
PEG (5Y)N/A
Graham Number143.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.36% | ||
| ROICexc | 14.9% | ||
| ROICexgc | 16.54% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)N/A
ROE(3y)-5.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 30.94 |
F-Score5
WACC7.52%
ROIC/WACC0.71
Cap/Depr(3y)176.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y867.29%
EPS Next 2Y297.24%
EPS Next 3Y171.03%
EPS Next 5Y106.11%
Revenue 1Y (TTM)64.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%96.6%
Revenue Next Year89.57%
Revenue Next 2Y60.07%
Revenue Next 3Y45.87%
Revenue Next 5Y33.99%
EBIT growth 1Y96.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.72%
EBIT Next 3Y205.97%
EBIT Next 5Y121.7%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.31%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE / 1AE.DE FAQ
What is the ChartMill fundamental rating of ARGENX SE (1AE.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 1AE.DE.
What is the valuation status for 1AE stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE (1AE.DE). This can be considered as Fairly Valued.
How profitable is ARGENX SE (1AE.DE) stock?
ARGENX SE (1AE.DE) has a profitability rating of 5 / 10.
What is the earnings growth outlook for ARGENX SE?
The Earnings per Share (EPS) of ARGENX SE (1AE.DE) is expected to grow by 867.29% in the next year.